LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.63 USD
0.00 (0.00%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $1.66 +0.03 (1.84%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
LAVA Therapeutics N.V. [LVTX]
Reports for Purchase
Showing records 1 - 12 ( 12 total )
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Key Takeaways from KOL Panels at Our Immune Cell Engager Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Key Takeaways form Our Immune Cell Engager Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Strategic Reprioritization of Clinical Pipeline; Lower PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Another Big-Pharma Vote of Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Unwarranted Sell-Off on LAVA-1207 Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Early Sign of LAVA-051?s Feasibility for Subcutaneous Administration; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Catalytic Clinical Updates Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
SITC Data Shed More Light on Gammabody?s PD Assessment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
A Pioneer in ?a T Cell Engagers; Initiate With Buy and a $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
|